Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LIVN 
LivaNova PLC (LIVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LIVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $65
1 Year Target Price $65
| 4 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.36% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.08B USD | Price to earnings Ratio - | 1Y Target Price 65 |
Price to earnings Ratio - | 1Y Target Price 65 | ||
Volume (30-day avg) 11 | Beta 0.93 | 52 Weeks Range 32.48 - 57.35 | Updated Date 08/29/2025 |
52 Weeks Range 32.48 - 57.35 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.14% | Operating Margin (TTM) 15.35% |
Management Effectiveness
Return on Assets (TTM) 5.12% | Return on Equity (TTM) -17.87% |
Valuation
Trailing PE - | Forward PE 15.04 | Enterprise Value 2916770497 | Price to Sales(TTM) 2.36 |
Enterprise Value 2916770497 | Price to Sales(TTM) 2.36 | ||
Enterprise Value to Revenue 2.23 | Enterprise Value to EBITDA 327.96 | Shares Outstanding 54601100 | Shares Floating 54410515 |
Shares Outstanding 54601100 | Shares Floating 54410515 | ||
Percent Insiders 0.38 | Percent Institutions 103.81 |
Upturn AI SWOT
LivaNova PLC
Company Overview
History and Background
LivaNova PLC was formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, Inc. Sorin was founded in 1956 in Italy and Cyberonics was founded in 1987 in the US. The merger aimed to create a global medical technology leader.
Core Business Areas
- Cardiac Surgery: Develops and manufactures devices for cardiac tissue repair, preservation, and cardiopulmonary support.
- Neuromodulation: Focuses on therapies for neurological disorders, primarily through vagus nerve stimulation (VNS) and other neuromodulation technologies. It also includes the SenTiva VNS Therapy System for the treatment of epilepsy.
Leadership and Structure
Damien McDonald serves as the Chief Executive Officer. The company operates with a functional organizational structure, with global operations and sales teams.
Top Products and Market Share
Key Offerings
- Cardio-Pulmonary: Extracorporeal Membrane Oxygenation (ECMO) and Heart-Lung Machines that support or replace the function of the heart and lungs during surgery. Market share data is commercially sensitive, but competitors include Medtronic and Getinge. Revenue contribution is significant to the Cardiac Surgery segment.
- VNS Therapy System: The SenTiva VNS Therapy System used for treating refractory epilepsy and treatment-resistant depression. Competitors include Medtronic and Abbott in Neuromodulation. The amount of users is proprietary information but its significant to the neuromodulation segment.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory scrutiny, and evolving patient needs. The neuromodulation market is growing due to increasing prevalence of neurological disorders and advancements in technology.
Positioning
LivaNova is positioned as a key player in both cardiac surgery and neuromodulation. Its competitive advantages include established brands and a diversified product portfolio.
Total Addressable Market (TAM)
The global medical device market is vast, projected to reach hundreds of billions of dollars. LivaNova targets specific segments within this market, including cardiac surgery and neuromodulation. Its positioning allows it to capitalize on a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong presence in cardiac surgery
- Established VNS therapy platform
- Global distribution network
- Innovative product development
- Experienced management team
Weaknesses
- Reliance on a few key products
- Vulnerability to pricing pressures
- Dependence on regulatory approvals
- Integration risks from past acquisitions
Opportunities
- Expanding into new geographic markets
- Developing next-generation neuromodulation devices
- Acquiring complementary technologies
- Partnering with research institutions
- Growing market for minimally invasive procedures
Threats
- Intense competition in medical device industry
- Evolving regulatory landscape
- Product liability risks
- Economic downturn affecting healthcare spending
- Emergence of disruptive technologies
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
LivaNova competes with larger medical device companies with more resources. LivaNova's focus on specific niches provides an advantage, but challenges related to competition still exist.
Major Acquisitions
ImThera Medical
- Year: 2014
- Acquisition Price (USD millions): 225
- Strategic Rationale: Strengthen LivaNova's portfolio by adding products addressing obstructive sleep apnea (OSA).
Growth Trajectory and Initiatives
Historical Growth: LivaNova's historical growth has been influenced by product launches, acquisitions, and market conditions. Analyzing historical revenue and earnings trends is necessary.
Future Projections: Future growth projections would depend on analyst estimates and company guidance. Key growth drivers would include new product adoption and expansion into new markets.
Recent Initiatives: Recent initiatives may include product launches, acquisitions, strategic partnerships, and cost-cutting measures. These actions are aimed at driving growth and improving profitability.
Summary
LivaNova is a key player in the neuromodulation and cardiac surgery markets with established brands. Its innovative products drive growth, but reliance on few key products remains a weakness. Expanding into new markets and leveraging strategic partnerships offer growth opportunities. The company faces competition and regulatory hurdles which must be carefully managed to ensure long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LivaNova PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-02-10 | CEO & Director Mr. Vladimir A. Makatsaria | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2900 | Website https://www.livanova.com |
Full time employees 2900 | Website https://www.livanova.com | ||
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.